

# INDEX

## A

Abscisic acid (ABA) ..... 185, 244–247  
 Acidity ..... 250  
 Acryloylated peptide substrates ..... 190, 192–193  
 Actin cytoskeleton ..... 207, 208, 211, 220  
 Actin filament organization ..... 208, 213  
 Agroinfiltration ..... 338, 340–342, 344, 345, 349  
 Alignment ..... 124, 125, 128–130  
*Alternaria brassicicola* ..... 225  
 Aniline blue staining ..... 196  
 ANOVA ..... 237  
 Anthocyanin inhibition ..... 68–69  
 Antimicrobial metabolites ..... 325  
 Anti-phospho ERK1/2 antibody ..... 157, 158, 160–161  
 Apoplast ..... 25, 234, 341, 349  
 Assay for transposase-accessible chromatin  
     (ATAC)-seq ..... 264  
 $\gamma$ -ATP32 ..... 190, 193  
 Autophagy ..... 109  
 Autoradiography ..... 161, 164  
 AvrPtoB ..... 111, 258  
 AvrRpt2 ..... 225

## B

Backcrossed segregants ..... 346  
 Bacterial flagellin ..... 39, 61, 146, 196,  
     233, 244, 249, 309  
 Bacterium-triggered stomatal closure ..... 237  
 Binding affinities ..... 2, 3, 10, 82, 83, 88, 350  
 Binding partners ..... 83, 87  
 Bioluminescence ..... 144, 149  
 Biosensor ..... 83  
 Biotrophic pathogens ..... 338

## C

Calcium-dependent protein kinases (CDPKs) ..... 14,  
     173–182  
 Calli ..... 311, 312, 315  
 Callose deposition ..... 27, 195–204, 250, 254  
 Carbohydrate-binding assay ..... 3, 6, 8  
 Cell wall integrity (CWI) ..... 13, 14  
 Cellulose ..... 3, 22, 32, 112, 114, 275–277, 319,  
     320, 322, 323

Chitin ..... 2, 3, 111, 134, 144, 185–193, 209, 212,  
     249, 309–315, 326, 332, 333  
 Chitin elicitor-receptor kinases (CERKs) ..... 111, 134  
 Chromatin accessibility ..... 263–271  
 Chromatographic profile ..... 26  
*cis*- and *trans*-elements ..... 264  
 Coaffinity purification ..... 81  
 Co-immunoprecipitation (Co-IP) ..... 168–170  
 Combinatorial genotypes ..... 224  
 Comparative glycomics ..... 14  
 ConA Sepharose ..... 57–59  
 Co-receptors ..... 2, 124, 285  
 Cotyledons ..... 27, 43, 44,  
     213, 218, 220  
 CRISPR associated protein 9 (Cas9) ..... 305  
 CRISPR-Cas9 system ..... 291–305  
 CRISPR RNA (crRNA) ..... 292  
 Cytoplasmic tail ..... 167

## D

Damage-associated molecular patterns  
     (DAMPs) ..... 13–22, 25  
 Deglycosylation ..... 62, 65  
 Disease resistance (R) gene ..... 250  
 DNA footprinting ..... 264  
 DNA methylation ..... 273  
 DNase cleavage ..... 264  
 DNase Hypersensitive Sites (DHSs) ..... 265, 269  
 DNase-seq ..... 265, 269, 270  
 Dynamic localization ..... 41

## E

E3 ubiquitin ligases ..... 110, 120  
 Effectoromics ..... 337–351  
 Effector-triggered immunity (ETI) ..... 212, 225  
 Electrospray ionization (ESI) ..... 26, 31, 32, 34, 35  
 Elf18 ..... 55, 56, 61, 63, 144, 209, 250, 318,  
     325, 326, 332, 333  
 Elongation factor-Tu (EF-Tu) ..... 55, 61, 155, 249, 325  
 Endoglycosidase H (Endo H) ..... 62, 68  
 Endoplasmic reticulum (ER) ..... 55, 61, 62  
 Endoplasmic reticulum quality control (ERQC) ..... 55, 56,  
     61–63  
 Endosomal puncta ..... 40, 41, 45–50, 52, 53

Epidermal impressions .....247  
 Epitope-tagged signalling protein .....3, 157  
 Ethylene ..... 27, 168, 169, 171  
 Ethylene-inducing xylanase (EIX) .....167–172

**F**

FASTA format ..... 125–126, 128  
 Fiji-TWS workflow .....41  
 FLAGELLIN SENSING/sensitive 2 (FLS2) ..... 53, 56,  
 61–65, 111, 155, 244, 285  
 Flavonoid accumulation .....64  
 Flg22 ..... 16, 19, 20, 39–44, 48, 50, 51, 53, 55,  
 61, 63–67, 72–75, 144–150, 152, 157, 158,  
 160–163, 174, 196–198, 201, 203, 209, 212, 225,  
 244, 246, 247, 249, 250, 256, 258, 259, 274, 318,  
 325, 326, 332, 333  
 FlgII-28 ..... 250, 255, 258, 259  
*fls2* ..... 64, 72, 73, 77  
 Fluorescein isothiocyanate (FITC) analysis .....2  
 For high-throughput screening .....350  
 Formaldehyde-Assisted Isolation of Regulatory  
 Elements (FAIRE)-seq .....264  
*Fusicoccum amygdali* .....244

**G**

Genome editing .....305  
 Genome-wide profiling .....274  
 $\beta$ -(1,3)-D-glucan polymer ..... 195  
 Glycans ..... 1–3, 10, 14, 16, 26, 61  
 Glycome profiling ..... 19–20  
 Glycosylation ..... 55–59, 62  
 Golden Gate assembly .....294  
 Golgi .....62  
 Green fluorescent protein (GFP) .....88, 97, 212, 319,  
 320, 322, 323  
 Growth arrest ..... 63–65, 77  
 Growth inhibition ..... 68–69, 72–73,  
 318, 320–322  
 Guard cells .....45, 220, 236, 237,  
 239, 244, 258

**H**

Haustorium .....243  
 Hemicelluloses ..... 14  
 Hidden markov model (HMM) .....124  
 High-throughput screening ..... 90, 144  
 Homologous recombination (HR) .....292, 317  
*Hyloperonospora parasitica* .....243  
 Hydathode .....244  
 Hydrolysis of homogalacturonan (HGA) .....25  
 Hydrophilic interaction chromatography (HILIC) .....26  
 Hydrophobicity .....250

**I**

Immunoblot analyses ..... 50, 56, 58, 59  
 Immunoprecipitation ..... 157, 173  
 In-gel kinase assay ..... 157, 161, 173–175, 177,  
 179–180, 186, 191  
 Innate immunity .....167  
 Internal endosomal compartments .....41  
 In vitro kinase assay .....163

**J**

Juxtamembrane domain .....123

**K**

Kinetics .....81–107, 147–152, 252, 257

**L**

Lenticels .....244  
 Ligand activity ..... 87, 105  
 Ligand-induced endocytosis .....53  
 Lignification ..... 325–334  
 Liquid chromatography (LC) ..... 26, 117, 135, 137  
 Luminol-based assay .....144  
 Lysin motif (LysM)-domain ..... 2, 309

**M**

Macrozyme ..... 158, 176, 180  
 Map-based cloning strategy .....285, 345  
 Mass spectrometry (MS) ..... 2, 26, 29, 32–35, 81, 117,  
 134, 135, 137, 139, 141  
 Matrix-assisted laser desorption/ionization  
 (MALDI) ..... 26, 32, 33  
 MicroRNAs (miRNAs) .....273, 274  
 Microscale thermophoresis (MST) analysis ..... 2, 82–84,  
 92–96  
 Mitogen-activated protein kinase (MAPK) cascades .....14,  
 133, 136, 155, 156, 164, 309  
 MNase-seq .....264  
 Moss ..... 186, 187, 191,  
 197, 317–323  
 Multiple loci .....296  
 Multisite Gateway LR recombination .....302  
 Mutagenesis .....288  
 Myelin basic protein (MBP) .....117, 118, 157–159,  
 161, 163, 165, 174, 181, 185–188, 190, 192–193

**N**

NADPH oxidases ..... 143, 309  
 Nail polish ..... 197, 199, 243–247  
 Necrotrophic pathogens ..... 225, 338  
 Network reconstitution .....223–230  
 Next generation sequencing ..... 274, 285–287

*N*-glycosylation..... 56, 59, 61–78  
Nitric oxide..... 25, 27

**O**

Oligosaccharyltransferase (OST) complex ..... 55, 56  
Osmotic stress ..... 186

**P**

PAMP-triggered immunity (PTI)..... 14, 124, 196, 212,  
233–240, 257, 258, 274, 325, 326  
Pathogen-associated molecular patterns (PAMPs) ..... 14, 16,  
123, 143–152, 178, 196, 201, 209, 212, 233, 244,  
245, 249, 273–283, 332–334  
Pathosystems ..... 234, 250, 274, 338  
Pattern recognition receptors (PRR) ..... 11, 14, 39, 59,  
78, 133, 143, 208, 249, 250, 325, 338  
Pectin..... 18, 25, 35  
Penetration ..... 196, 243  
Peptidoglycan (PGN)..... 1–11, 271, 309  
Peroxidases ..... 11, 16, 19, 144, 145, 195, 251,  
311, 314, 315, 326  
Phenolics ..... 195, 331, 333  
Phosphopeptides ..... 134, 135, 137, 139–141  
Phosphorylation target ..... 175  
Phylogenetic tree ..... 125, 127, 129  
*Physcomitrella patens*..... 186, 323  
Phytopathogenic microbes ..... 208  
Plant U-box proteins (PUBs) ..... 110  
Plasma membrane (PM) ..... 39, 41, 46, 47, 50, 53,  
61, 62, 65, 143, 155, 213, 309  
Point mutations ..... 134, 135, 175  
Polygalacturonase-inhibiting proteins (PGIPs) ..... 25  
Polygalacturonases (PGs) ..... 25, 28  
Polygalacturonic acid (PGA) ..... 26, 27, 29, 30  
Polymorphisms ..... 285, 287–289  
Ponceau staining..... 187, 192, 313  
Posttranslational modifications..... 62  
Programmed cell death..... 62  
Protein expression and purification ..... 4–5, 112–114  
Protein phosphatases 2C (PP2C)..... 185  
Protoplasts ..... 156–159, 162, 163, 165, 174–179, 181, 182  
Protoplast transient expression system..... 174  
Protospacer adjacent motif (PAM)..... 292, 297, 303  
*Pseudomonas syringae*..... 111, 196, 198, 201,  
209, 210, 234, 235, 237–239, 244, 250, 254, 255,  
258, 259, 271, 274

**Q**

Quadruple deletion..... 224, 229  
Quantitative disease resistance (QDR)..... 326  
Quantitative evaluation ..... 207–221  
Quantitative phenotype..... 224, 226

**R**

Reactive oxygen species (ROS)..... 14, 25, 134, 152,  
168–171, 195, 196, 250–253, 257, 309, 315, 317,  
326, 328–329, 332, 333  
Receptor-like kinases (RLKs)..... 123–130, 133,  
167, 309  
Resistance gene enrichment sequencing (RenSeq)..... 341  
RNA silencing..... 273

**S**

Salicylic acid (SA) ..... 196, 233, 244  
*Sclerotinia sclerotiorum* ..... 244  
SDS-PAGE and western blotting ..... 5, 8–9  
Sequence complementarities ..... 273  
Sequence specific nuclease (SSN)..... 292  
Serine/threonine kinase domain ..... 123  
SHOREmap..... 285  
Single-domain antibodies (sdAbs,  
also called 'nanobodies') ..... 88  
Small interfering RNAs (siRNAs) ..... 273  
Small non-coding RNAs (smRNAs)..... 273, 274,  
281, 282  
Small RNA-seq ..... 281  
Snf1-related kinase family (SnRK)..... 185, 186  
26S proteasome ..... 109  
Spinning disc confocal microscopy  
(SDCM) ..... 40–42, 44, 51  
Stomatal aperture width ..... 234, 236, 238–240  
Stomatal immunity..... 234, 237, 238  
*Streptococcus pyogenes* (SpCas9) ..... 291, 297  
Strong cation exchange (SCX) ..... 136–139, 141  
Student's *t*-test ..... 40, 218, 237, 239, 240, 333  
Subnetwork interaction ..... 223–230  
Surface plasmon resonance (SPR) ..... 2, 83–92, 94,  
96–102, 104, 105  
Suspension-cultured cells ..... 315

**T**

TAL effector nuclease (TALEN) ..... 292  
Tandem mass tags (TMT) ..... 134–136, 138–140  
Thermophoretic force..... 83  
Transactivating CRISPR RNA (tracrRNA)..... 292  
Transcript cleavage ..... 273  
Translational repression ..... 273  
Tunicamycin ..... 62, 63, 65, 67, 69, 78  
Type-III secretion system (T3SS) ..... 196, 201

**U**

Ubiquitination ..... 109–120  
Ultra-performance liquid chromatography  
(UPLC) analysis ..... 4, 9

**V**

Vesicular trafficking protein .....41

**X**

*Xanthomonas campestris*.....244

**Y**

Yeast two hybrid .....168

**Z**

Zinc finger nuclease (ZFN).....292